Revolution Medicines Announces Preliminary Clinical Data for RMC-9805

Details

reported preliminary clinical safety, tolerability, and activity data for RMC-9805, a RAS(ON) oral tri-complex G12D-selective inhibitor, in patients with previously treated solid tumors harboring KRAS G12D mutations. The data, as of a cutoff date of September 2, 2024, showed gastrointestinal-related toxicities as the most common treatment-related adverse events. The Company observed no treatment-related Grade 4 or 5 adverse events or serious adverse events, and there were no treatment discontinuations due to adverse events. The best percentage change in tumor size from baseline for patients with pancreatic ductal adenocarcinoma in the second-line or later setting showed an objective response rate of 30% and a disease control rate of 80%. The Company plans to continue the development of RMC-9805 as a single agent and in combination with other therapies.

Items reported

About Revolution Medicines Inc.

Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.